SSRI and SNRI use during pregnancy and the risk of persistent pulmonary hypertension of the newborn

Aim The use of selective serotonin reuptake inhibitors (SSRIs) in late pregnancy may be associated with an increased risk of persistent pulmonary hypertension of the newborn (PPHN). Limited data are available on the risk of PPHN associated with serotonin norepinephrine reuptake inhibitors (SNRIs). We aimed to quantify both associations. Methods Using data from the Quebec Pregnancy Cohort between 1998 and 2009, we included women covered by the provincial drug plan who had a singleton live birth. Exposure categories were SSRI, SNRI and other antidepressant use; non‐users were considered as the reference category. Generalized estimating equation models were used to obtain risk estimates and 95% confidence intervals (CIs). Confounding by indication was minimized by adjusting for history of maternal depression/anxiety before pregnancy. Results Overall, 143 281 pregnancies were included; PPHN was identified in 0.2% of newborns. Adjusting for maternal depression, and other potential confounders, SSRI use during the second half of pregnancy was associated with an increased risk of PPHN [adjusted odds ratio (aOR) 4.29, 95% CI 1.34, 13.77] compared with non‐use of antidepressants; SNRI use during the same time window was not statistically associated with the risk of PPHN (aOR 0.59, 95% CI 0.06, 5.62). Use of SSRIs and SNRIs before the 20th week of gestation was not associated with the risk of PPHN. Conclusions Use of SSRIs in the second half of pregnancy was associated with the risk of PPHN. Given our results on SNRIs and the lack of statistical power for these analyses, it is unclear whether SNRI use during pregnancy also increases the risk of PPHN.

[1]  A. Bérard,et al.  Can We Rely on Pharmacy Claims Databases to Ascertain Maternal Use of Medications during Pregnancy? , 2017, Birth defects research.

[2]  S. Hernández-Díaz,et al.  Antidepressant use late in pregnancy and risk of persistent pulmonary hypertension of the newborn. , 2015, JAMA.

[3]  Mary K. Kowal,et al.  Validity of maternal and infant outcomes within nationwide Medicaid data , 2014, Pharmacoepidemiology and drug safety.

[4]  A. Bérard,et al.  The Quebec Pregnancy Cohort – Prevalence of Medication Use during Gestation and Pregnancy Outcomes , 2014, PloS one.

[5]  C. Dennis,et al.  Prenatal exposure to antidepressants and persistent pulmonary hypertension of the newborn: systematic review and meta-analysis , 2014, BMJ : British Medical Journal.

[6]  L. Blais,et al.  Validity of congenital malformation diagnostic codes recorded in Québec's administrative databases , 2013, Pharmacoepidemiology and drug safety.

[7]  C. Torp-Pedersen,et al.  Prevalence of Antidepressant Use during Pregnancy in Denmark, a Nation-Wide Cohort Study , 2013, PloS one.

[8]  A. Bérard,et al.  Epidemiology of major congenital malformations with specific focus on teratogens. , 2013, Current drug safety.

[9]  M. Gissler,et al.  Selective serotonin reuptake inhibitors during pregnancy and risk of persistent pulmonary hypertension in the newborn: population based cohort study from the five Nordic countries , 2011, BMJ : British Medical Journal.

[10]  Brad M. Dolinsky,et al.  Persistent Pulmonary Hypertension of the Newborn Is Associated with Mode of Delivery and Not with Maternal Use of Selective Serotonin Reuptake Inhibitors , 2010, American journal of perinatology.

[11]  R. Steinhorn Neonatal pulmonary hypertension , 2010, Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.

[12]  B. Källén,et al.  Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data , 2010, Psychological Medicine.

[13]  David J. Loren,et al.  Antidepressant medication use and risk of persistent pulmonary hypertension of the newborn , 2009, Pharmacoepidemiology and drug safety.

[14]  Tara R. Lang,et al.  Congenital heart disease associated with selective serotonin reuptake inhibitor use during pregnancy. , 2009, Mayo Clinic proceedings.

[15]  A. Lacasse,et al.  Validity of perinatal pharmacoepidemiologic studies using data from the RAMQ administrative database. , 2009, The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique.

[16]  L. Blais,et al.  Agreement between administrative databases and medical charts for pregnancy‐related variables among asthmatic women , 2008, Pharmacoepidemiology and drug safety.

[17]  L. Shulman Increasing use of antidepressants in pregnancy , 2008 .

[18]  J. Belik,et al.  Prenatal exposure to fluoxetine induces fetal pulmonary hypertension in the rat. , 2007, American journal of respiratory and critical care medicine.

[19]  S. Hernández-Díaz,et al.  Selective Serotonin-Reuptake Inhibitors and Risk of Persistent Pulmonary Hypertension of the Newborn , 2006, The New England journal of medicine.

[20]  N. Sussman SNRIs Versus SSRIs: Mechanisms of Action in Treating Depression and Painful Physical Symptoms , 2003 .

[21]  M. Hamon,et al.  Is the serotonin transporter involved in the pathogenesis of pulmonary hypertension? , 2002, The Journal of laboratory and clinical medicine.

[22]  H. Sørensen,et al.  Improvement of drug exposure data in a registration of congenital anomalies. Pilot-study: pharmacist and mother as sources for drug exposure data during pregnancy. EuroMAP Group. Europen Medicine and Pregnancy Group. , 1999, Teratology.

[23]  S. Abman New developments in the pathogenesis and treatment of neonatal pulmonary hypertension , 1999, Pediatric pulmonology. Supplement.

[24]  T. McMahon,et al.  Analysis of responses to serotonin in the pulmonary vascular bed of the cat. , 1993, Journal of applied physiology.

[25]  J. Hageman,et al.  Persistent pulmonary hypertension of the newborn. Trends in incidence, diagnosis, and management. , 1984, American journal of diseases of children.